Abstract
AbstractAmong the N‐containing heterocyclic compounds, quinazoline‐4‐(3H)‐one derivatives have been the center of attraction of medicinal and synthetic chemists due to their excellent versatility in biological activities that are witnessed by many approved drugs available in the market which contains quinazoline as main pharmacophore unit. This review mainly focuses the recent and current progresses in quinazoline derivatives as an acetylcholinesterase (AChE) and monoamine oxidase (MAO)‐B inhibitors. The review has leanings towards the molecular determinants and structure‐activity relationships (SAR) of quinazoline derivatives on AChE and MAO inhibitory potencies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
